Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current pharmaceutical design

• Publication date

  2013-07-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/1381612811319250011PMID 23339739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Radiosynthesis of a ⁶⁸Ga labeled matrix metalloproteinase inhibitor as a potential probe for PET imaging.

  2012cited by this paper
• Radioactive smart probe for potential corrected matrix metalloproteinase imaging.

  2012influential reference
• A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.

  2012cited by this paper
• A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.

  2012cited by this paper
• Conditionally Replicating Adenovirus Expressing TIMP2 Increases Survival in a Mouse Model of Disseminated Ovarian Cancer

  2011cited by this paper
• The MMP inhibitor (R)-2-(N-benzyl-4-(2-[18F]fluoroethoxy)phenylsulphonamido)-N-hydroxy-3-methylbutanamide: Improved precursor synthesis and fully automated radiosynthesis.

  2011cited by this paper
• Targeted Imaging of the Spatial and Temporal Variation of Matrix Metalloproteinase Activity in a Porcine Model of Postinfarct Remodeling: Relationship to Myocardial Dysfunction

  2011cited by this paper
• In Vivo Positron Emission Tomography Imaging of Protease Activity by Generation of a Hydrophobic Product from a Noninhibitory Protease Substrate

  2011cited by this paper
• Towards kit-like 18F-labeling of marimastat, a noncovalent inhibitor drug for in vivo PET imaging cancer associated matrix metalloproteases

  2011cited by this paper
• Matrix Metalloproteinase Activation Predicts Amelioration of Remodeling After Dietary Modification in Injured Arteries

  2011cited by this paper
• Tissue inhibitors of metalloproteinases

  2011cited by this paper
• Tumor Targeting of MMP-2/9 Activatable Cell-Penetrating Imaging Probes Is Caused by Tumor-Independent Activation

  2011cited by this paper
• Atherosclerosis Plaque Heterogeneity and Response to Therapy Detected by In Vivo Molecular Imaging of Matrix Metalloproteinase Activation

  2011cited by this paper
• Tumour-targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3

  2010cited by this paper
• Radiofluorinated Pyrimidine‐2,4,6‐triones as Molecular Probes for Noninvasive MMP‐Targeted Imaging

  2010cited by this paper
• Noninvasive monitoring the biology of atherosclerotic plaque development with radiolabeled annexin V and matrix metalloproteinase inhibitor in spontaneous atherosclerotic mice

  2010cited by this paper
• Novel matrix metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer.

  2010cited by this paper
• Effect of an antimicrobial agent on atherosclerotic plaques: assessment of metalloproteinase activity by molecular imaging.

  2010cited by this paper
• Radioimmunodetection of membrane type-1 matrix metalloproteinase relevant to tumor malignancy with a pre-targeting method.

  2010cited by this paper
• Molecular Imaging of Matrix Metalloproteinase Activation to Predict Murine Aneurysm Expansion In Vivo

  2010cited by this paper
• Matrix metalloproteinases.

  2010cited by this paper
• Cancer esearch apeutics , Targets , and Chemical Biology el Matrix Metalloproteinase Inhibitor [ 18 F ] Marimastat-ltrifluoroborate as a Probe for In vivo Positron R ission Tomography Imaging in Cancer

  2010cited by this paper
• Membrane Type 1 Matrix Metalloproteinase Detection in Tumors, Using the Iodinated Endogenous [123I]-Tissue Inhibitor 2 of Metalloproteinases as Imaging Agent

  2010cited by this paper
• Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model.

  2010cited by this paper
• Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques

  2010cited by this paper
• Molecular Imaging of Matrix Metalloproteinase Expression in Atherosclerotic Plaques of Mice Deficient in Apolipoprotein E or Low-Density-Lipoprotein Receptor

  2009cited by this paper
• Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis

  2009cited by this paper
• Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors.

  2009cited by this paper
• Development of an optimized activatable MMP-14 targeted SPECT imaging probe.

  2009cited by this paper
• A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies.

  2009cited by this paper
• Zinc‐Binding Groups Modulate Selective Inhibition of MMPs

  2008cited by this paper
• 18F-labelled cardiac PET tracers: selected probes for the molecular imaging of transporters, receptors and proteases

  2008cited by this paper
• Imaging matrix metalloproteinases in cancer

  2008cited by this paper
• Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy.

  2008cited by this paper
• Traversing the coordination chemistry and chemical biology of hydroxamic acids

  2008cited by this paper
• Matrix metalloproteinase inhibitors as anticancer agents.

  2008influential reference
• Molecular Imaging of Activated Matrix Metalloproteinases in Vascular Remodeling

  2008cited by this paper
• Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.

  2007cited by this paper
• Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.

  2007cited by this paper
• Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases

  2007cited by this paper
• A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo.

  2007cited by this paper
• Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).

  2007cited by this paper
• Can matrix metalloproteinase inhibitors provide a realistic therapy in cardiovascular medicine?

  2007influential reference
• Chemical design of a radiolabeled gelatinase inhibitor peptide for the imaging of gelatinase activity in tumors.

  2007cited by this paper
• In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models.

  2006cited by this paper
• Valine-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumor imaging agents.

  2006cited by this paper
• C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.

  2005cited by this paper
• Tryptophane-Based Biphenylsulfonamide Matrix Metalloproteinase Inhibitors as Tumor Imaging Agents

  2005cited by this paper
• Noninvasive Targeted Imaging of Matrix Metalloproteinase Activation in a Murine Model of Postinfarction Remodeling

  2005influential reference
• Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents.

  2005cited by this paper
• Synthesis, quality control and in vivo evaluation of [I-123] rhTIMP-2, a potential tumour-imaging agent

  2005cited by this paper
• New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents.

  2004cited by this paper
• Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide.

  2004cited by this paper
• Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo.

  2004cited by this paper
• Scintigraphic Imaging of Matrix Metalloproteinase Activity in the Arterial Wall In Vivo

  2004cited by this paper
• Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4'-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4'-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbutanamide.

  2004cited by this paper
• Carbon-11 labelling of an N-sulfonylamino acid derivative: a potential tracer for MMP-2 and MMP-9 imaging

  2003cited by this paper
• Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester.

  2003cited by this paper
• Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.

  2003cited by this paper
• The ADAMs family of metalloproteases: multidomain proteins with multiple functions.

  2003influential reference
• Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor.

  2003cited by this paper
• Synthesis of MMP inhibitor radiotracer [11C]CGS 25966, a new potential pet tumor imaging agent

  2003cited by this paper
• ADAMs: modulators of cell-cell and cell-matrix interactions.

  2003influential reference
• Molecular determinants of metalloproteinase substrate specificity

  2002cited by this paper
• Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents.

  2002cited by this paper
• Synthesis of MMP inhibitor radiotracers [11C]methyl-CGS 27023A and its analogs, new potential PET breast cancer imaging agents

  2002cited by this paper
• Design and synthesis of fluorine‐18 labeled matrix metalloproteinase inhibitors for cancer imaging

  2002cited by this paper
• Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model.

  2001cited by this paper
• Synthesis and characterization of 111In-DTPA-N-TIMP-2: a radiopharmaceutical for imaging matrix metalloproteinase expression.

  2001cited by this paper
• In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection

  2001cited by this paper
• In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection.

  2001cited by this paper
• Development of matrix metalloproteinase inhibitors in cancer therapy.

  2001cited by this paper
• In vivo imaging of proteolytic enzyme activity using a novel molecular reporter.

  2000cited by this paper
• Design and therapeutic application of matrix metalloproteinase inhibitors.

  1999influential reference
• Matrix Metalloproteinases*

  1999cited by this paper
• Tumor targeting with a selective gelatinase inhibitor

  1999cited by this paper
• Kinetic analysis of the mechanism of interaction of full-length TIMP-2 and gelatinase A: evidence for the existence of a low-affinity intermediate.

  1998cited by this paper
• Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.

  1997cited by this paper
• Matrilysin-inhibitor complexes: common themes among metalloproteases.

  1996cited by this paper
• Tissue inhibitors of matrix metalloendopeptidases.

  1995cited by this paper
• Structural features of a superfamily of zinc-endopeptidases: the metzincins.

  1995cited by this paper
• Families of zinc metalloproteases

  1994cited by this paper
• The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity.

  1991cited by this paper
• Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP).

  1990cited by this paper

• The Multifaceted Role of Connexins in Tumor Microenvironment Initiation and Maintenance

  2023cites this paper
• In silico evaluation of new mangiferin-based Positron Emission Tomography radiopharmaceuticals through the inhibition of metalloproteinase-9.

  2023cites this paper
• Druggability of Targets for Diagnostic Radiopharmaceuticals.

  2023cites this paper
• Abdominal Aortic Aneurysm and PET/CT: From Molecular Mechanisms to Potential Molecular Imaging Targets

  2023cites this paper
• Labelling Matrix Metalloproteinases.

  2023cites this paper
• Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology

  2022cites this paper
• Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade

  2022cites this paper
• The Tumor Proteolytic Landscape: A Challenging Frontier in Cancer Diagnosis and Therapy

  2021cites this paper
• Towards Optimized Bioavailability of 99mTc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity

  2021cites this paper
• Dynamic change of MMP-9 in diabetic stroke visualized by optical imaging and treated with CD28 superagonist.

  2021cites this paper
• Macrophage imaging and subset analysis using single-cell RNA sequencing

  2021cites this paper
• Current and novel radiopharmaceuticals for imaging cardiovascular inflammation.

  2020cites this paper
• Hydroxamate-Based Selective Macrophage Elastase (MMP-12) Inhibitors and Radiotracers for Molecular Imaging.

  2020cites this paper
• Evolving Role of PET in Detecting and Characterizing Atherosclerosis.

  2019cites this paper
• Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer.

  2019cites this paper
• Pre-labelling versus direct labelling of anthrax proteins for imaging of matrix metalloproteinases activity using DOTA-GA.

  2019cites this paper
• Chemical Probes Targeting Proteases for Imaging and Diagnostics in Cancer

  2018cites this paper
• The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies

  2018cites this paper
• PET Imaging in Psychoneuroimmunology Research.

  2018cites this paper
• Synthesis and PreliminaryIn VitroandIn VivoEvaluation of Thiirane‐Based Slow‐Binding MMP Inhibitors as Potential Radiotracers for PET Imaging

  2018cites this paper
• Design, (Radio)Synthesis, and in Vitro and in Vivo Evaluation of Highly Selective and Potent Matrix Metalloproteinase 12 (MMP-12) Inhibitors as Radiotracers for Positron Emission Tomography.

  2018cites this paper
• A New Perspective in Utilizing MMP-9 as a Therapeutic Target for Alzheimer’s Disease and Type 2 Diabetes Mellitus

  2018cites this paper
• Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid

  2018cites this paper
• Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment

  2018cites this paper
• Multimodality Preclinical Imaging in Inflammatory Diseases

  2018cites this paper
• One Coin, No Need to Flip: Shared PET Targets in Cancer and Coronary Artery Disease.

  2017cites this paper
• Novel molecular imaging ligands targeting matrix metalloproteinases 2 and 9 for imaging of unstable atherosclerotic plaques

  2017cites this paper
• Evaluation of [18 F]BR420 and [18 F]BR351 as radiotracers for MMP-9 imaging in colorectal cancer.

  2017cites this paper
• Progress and Challenges in the Development of PET Ligands to Aid CNS Drug Discovery

  2017cites this paper
• Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles

  2017cites this paper
• Imaging the Tumor Microenvironment.

  2017cites this paper
• Radiolabeled Selective Matrix Metalloproteinase 13 (MMP-13) Inhibitors: (Radio)Syntheses and in Vitro and First in Vivo Evaluation.

  2017cites this paper
• Riding the metalloproteinase roller coaster

  2017cites this paper
• Role of molecular imaging with positron emission tomographic in aortic aneurysms.

  2017cites this paper
• Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT

  2017cites this paper
• Syntheses of Radioiodinated Pyrimidine-2,4,6-Triones as Potential Agents for Non-Invasive Imaging of Matrix Metalloproteinases

  2017cites this paper
• Cellular and molecular players in vascular and left ventricular remodeling

  2017cites this paper
• Imaging neuroinflammation in Alzheimer’s and other dementias: recent advances and future directions

  2016cites this paper
• Exploration of the labeling of [11C]tubastatin A at the hydroxamic acid site with [11C]carbon monoxide.

  2016cites this paper
• Synthesis and in Vitro and in Vivo Evaluation of MMP-12 Selective Optical Probes.

  2016cites this paper
• Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: How chemical modifications affect pharmacokinetics and metabolic stability.

  2016cites this paper
• The Clinical Value of Cardiac PET in Heart Failure

  2016cites this paper
• Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications

  2016cites this paper
• Synthesis, in vitro and in vivo evaluation of MMP-12 selective optical probes

  2016cites this paper
• 8 – Atherosclerotic plaque

  2015cites this paper
• In vivo biodistribution of radiolabeled MMP-2/9 activatable cell-penetrating peptide probes in tumor-bearing mice.

  2015cites this paper
• The advancement of human serum albumin-based molecular probes for molecular imaging.

  2015cites this paper
• Design, (radio)synthesis and applications of radiolabelled matrix metalloproteinase inhibitors

  2015cites this paper
• Translational applications of molecular imaging in cardiovascular disease and stem cell therapy.

  2015cites this paper
• Design, (radio)synthesis and applications of radiolabelled matrix metalloproteinase inhibitors for PET

  2015cites this paper
• Development and preclinical comparison of two non- peptidomimetic MMP/ADAM inhibitors for PET

  2015cites this paper
• Évaluation de ligands pour l’imagerie moléculaire de la néoangiogenèse tumorale

  2015cites this paper
• Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions

  2015cites this paper
• Moving targets: Emerging roles for MMPs in cancer progression and metastasis.

  2015cites this paper
• Study of the binding interaction between fluorinated matrix metalloproteinase inhibitors and Human Serum Albumin.

  2014cites this paper
• Role of RORyt+ innate lymphoid tissue inducer cells within breast cancer microenvironments

  2014cites this paper
• Longitudinal Imaging of Cancer Cell Metastases in Two Preclinical Models: A Correlation of Noninvasive Imaging to Histopathology

  2014cites this paper
• Neural ECM and epilepsy.

  2014cites this paper
• PET/CT imaging in cancer: Current applications and future directions

  2014cites this paper
• Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging.

  2014cites this paper
• In vivo Overhauser-enhanced MRI of proteolytic activity.

  2014cites this paper
• The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis.

  2014cites this paper
• New radiotracers for imaging of vascular targets in angiogenesis-related diseases.

  2014cites this paper
• BJRD14065 1..15

  2014cites this paper
• Is there new hope for therapeutic matrix metalloproteinase inhibition?

  2014cites this paper
• Multimarker approach for identifying and documenting mitigation of cardiovascular risk.

  2013cites this paper
• Imaging neuroinflammation in Alzheimer’s disease and other dementias: Recent advances and future directions

  year unknowncites this paper